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Introduction {#sec1}
============

Since the first report of blood cell production from embryonic stem cells (ESCs) ([@bib8]), it has been a long-term goal to use *in vitro* cultures to produce definitive hematopoietic progenitor cells (HPCs) and hematopoietic stem cells (HSCs). With the advent of patient-specific induced pluripotent stem cells (iPSCs), this approach could be used for treating blood disorders without the adverse effects of rejection. Some progress toward differentiation into distinct blood lineages has been made through addition of growth factors to ESC/iPSC differentiation cultures ([@bib9], [@bib25], [@bib39]), and limited *in vivo* repopulation has been achieved by overexpression of transcription factors in ESCs/iPSCs/endothelial cells ([@bib30], [@bib48]). More fundamental studies on ESC hematopoietic differentiation have provided some insight into whether such *ex vivo* cultures recapitulate *in vivo* hematopoietic development ([@bib4], [@bib18], [@bib27]).

The natural development of the hematopoietic system occurs in spatiotemporally distinct waves (reviewed in [@bib10], [@bib22]). The first blood cell production occurs in the yolk sac (YS) at mouse embryonic day 7 (E7), producing a transient cell population of mainly primitive erythrocytes ([@bib38]). Definitive erythrocytes and myeloid cells appear in the YS starting at E8.25 and originate from erythroid-myeloid progenitors (EMPs) ([@bib13]). Shortly thereafter, HPCs with erythroid-myeloid-lymphoid potential ([@bib15]), lymphoid progenitors ([@bib1], [@bib28]), and neonatal-engrafting hematopoietic cells arise ([@bib51]). HSC production is initiated in the final wave starting at E10.5 in the aorta-gonads-mesonephros (AGM) ([@bib32], [@bib34]).

The *Gata2* transcription factor plays a pivotal intrinsic role in EMP, HPC, and HSC generation in the embryo ([@bib6], [@bib14], [@bib29], [@bib49]). *Gata2*^*−/−*^ mouse and human (h) ESCs show defective hematopoietic differentiation ([@bib16], [@bib49]), and most hESC-derived HPCs are marked by GATA2 reporter expression, although it is uncertain whether this reporter parallels endogenous GATA2 expression ([@bib17]). In our *Gata2Venus* (*G2V*) mice, in which levels of Gata2 expression are normal, it was found that Gata2 marks all HSCs and majority of HPCs. Gata2 is expressed in endothelial cells of the E8.5 YS and dorsal aorta ([@bib33], [@bib40]), E10.5 aortic hemogenic endothelial cells (HECs) ([@bib11]), and C-KIT^+^CD31^+^ intra-aortic hematopoietic cluster cells (IAHCs) ([@bib20]). Thus, the *G2V* reporter facilitates the examination of HPCs and HSCs as they emerge in the mouse embryo. *Ly6a*(SCA1)*GFP* (*LG*) is another reporter that marks embryonic aortic cells. All HSCs, some HECs, IAHCs ([@bib3], [@bib5], [@bib28], [@bib46]), and embryonic cells with lymphoid potential ([@bib5], [@bib28]) are LG expressing. Vital imaging of the E10.5 mouse aorta shows endothelial-to-hematopoietic transition (EHT) of these cells ([@bib2]). However, unlike the *G2V* reporter, LG^+^ cells are found in the AGM only beginning at late E9 ([@bib31]), and thus, this distinguishes the later induction of an intraembryonic definitive HPC/HSC program.

Taking into account the complex spatiotemporal organization of *in vivo* blood development, it is likely that the ability to robustly generate definitive HPC/HSC *in vitro* depends on the spatiotemporal programs occurring during ESC differentiation, and requires enrichment methodologies with pivotal reporters to identify/isolate the cells of interest. Such reporters are a powerful tool for studying the dynamics of functional HPC/HSC generation *in vitro* ([@bib18], [@bib27], [@bib36]) and their relationship to normal HPC/HSC development.

Here we examine the expression of *G2V* and *LG* reporters and the emergence of functional hematopoietic cells in a stepwise *in vitro* system of induction, enrichment, and differentiation of ESCs. We show that the temporal wave-like *G2V* reporter expression corresponds to waves of primitive and definitive hematopoietic emergence. *Gata2* is co-expressed in these cells with hematopoietic transcription factors and marks functional HPCs emerging in the sequential waves. *LG* expression is specific to HPCs that emerge/persist in later differentiation stages, marking definitive progenitors with erythroid, myeloid, and/or B-lymphoid potential. This is confirmed in double reporter ESCs to show that *in vitro* differentiation occurs in stages that approximate the *in vivo* hematopoietic cell generation in mouse embryos.

Results {#sec2}
=======

Hematopoietic and Endothelial Potential of *Gata2*^+^ ESCs {#sec2.1}
----------------------------------------------------------

Hematopoiesis is initiated by FLK1^+^ cells, which are able to generate endothelial and hematopoietic progenitors ([@bib4], [@bib18]). In hESC differentiation cultures, KDR^+^ cells develop in response to bone morphogenetic protein 4 (BMP4) between 72 and 96 hr and represent a transient population that precedes the onset of primitive hematopoiesis ([@bib24]). To directly examine the relationship of *Gata2* expression and hematopoietic differentiation of mouse ESCs, we used a *G2V* reporter ESC line ([@bib20]) that facilitates tracing and isolation of live Gata2^+^ cells by Venus fluorescence ([Figure S1](#mmc1){ref-type="supplementary-material"}), while preserving normal Gata2 endogenous levels. This is critical, since altered Gata2 levels severely affect the production and expansion of embryonic HSCs and HPCs and affect HSC robustness in the adult ([@bib29], [@bib42]), and dysregulation leads to leukemic syndromes ([@bib21]). To examine whether Gata2^+^ cells possess endothelial or hematopoietic cell characteristics, we induced *G2V* ESC differentiation in the presence of BMP4 ([Figure 1](#fig1){ref-type="fig"}A) and analyzed them at days 3--6. FLK1^+^V^−^, FLK1^−^V^+^, FLK1^+^V^+^, and FLK1^−^V^−^ cells sorted by fluorescence-activated cell sorting (FACS) were evaluated in hematopoietic colony-forming unit---cell (CFU-C) and Matrigel endothelial assays.Figure 1G2V-Expressing Cells in Early Differentiation Culture Possess Primitive Erythroid and Endothelial Potential(A) Scheme of ESC differentiation. BMP4 was present on days 0--3. FACS-analyzed/sorted embryoid body (EB) cells were tested in CFU-C (colony-forming unit---cell) and Matrigel assays.(B) Dot plots for FLK1 (F) and Venus (V) expression from day 3 (d3) to day 6 (n = 3).(C) Quantification of FACS data in (B) showing percentage of F^+^V^−^, F^+^V^+^, and F^−^V^+^ cells at days 3--6 (n = 3).(D) Bar graphs showing CFU-C/10^4^ F^+^V^−^, F^+^V^+^, F^−^V^+^, and F^−^V^−^ cells at days 4--6 (n = 4). Colony types are indicated by color. CFU-M, macrophage; BFU-E, definitive erythroid; CFU-EryP, primitive erythroid.(E) Representative images showing endothelial tubules in Matrigel cultures of F^+^V^−^, F^+^V^+^, F^−^V^+^, and F^−^V^−^ cells from day-4 differentiated ESCs. Scale bars, 200 μm.(F) Quantification of (E) (tubules/2 × 10^4^ cells; n = 3).Data are shown as means ± SEM. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

At days 3 and 4, the majority of V^+^ cells co-expressed FLK1 (67% and 76%, respectively) ([Figure 1](#fig1){ref-type="fig"}B). As the FLK1^+^V^+^ cell frequency decreased at day 5, the V^+^ single positive population became more prominent and FLK1^+^ cell frequency decreased ([Figure 1](#fig1){ref-type="fig"}C). Only the V^+^ fraction produced CFU-C ([Figure 1](#fig1){ref-type="fig"}D). CFU-Cs were detected from day 4 onward, with the main colony type being CFU-EryP (---primitive erythroid). Few CFU-M (---macrophages) and burst-forming units---definitive erythroid (BFU-E) progenitors were observed. Although the majority of colonies were scored in the FLK1^−^V^+^ population (24 ± 13, 16 ± 11, and 23.2 ± 10 CFU-C/10^4^ cells at days 4, 5, and 6, respectively), CFU-C were also detected in the FLK1^+^V^+^ cells at day 4.

To test the day-4 endothelial potential of ESCs (time of highest CFU-C potential in FLK1^+^V^+^ fraction), we quantified tubule formation of sorted cells ([Figures 1](#fig1){ref-type="fig"}E and 1F). The highest frequency was in FLK1^+^V^−^ cells (100 tubules/2 × 10^4^ cells). FLK1^+^V^+^ cells also showed endothelial potential (30 tubules/2 × 10^4^ cells), demonstrating that in addition to hematopoietic potential, some FLK1^+^V^+^ cells are capable of endothelial differentiation. This transient Gata2-expressing FLK1^+^ population emerges at day 4 and rapidly decreases thereafter. Thus, Gata2-expressing FLK1^+^ cells give rise to the earliest blood cells.

Temporally Defined *Gata2* Expression Waves Are Detected in ESC Cultures {#sec2.2}
------------------------------------------------------------------------

The temporal dynamics of Gata2 expression was characterized in ESC hematopoietic differentiation from days 4 to 14 by FACS ([Figures 2](#fig2){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}D). V^+^ cells were detected throughout the time course and showed wave-like dynamics with peaks of increased V^+^ cell frequency. Compared with day 4, day-6 V^+^ cell percentages were significantly higher (5.5-fold) ([Figure 2](#fig2){ref-type="fig"}A) and then decreased at days 7--10. V^+^ cell percentages increased again at day 11, decreased at day 13, and increased again at day 14 (RNA analysis in [Figure S1](#mmc1){ref-type="supplementary-material"}E). *Gata2* RNA expression ([Figure 2](#fig2){ref-type="fig"}B) showed increases at days 6 and 14 that correspond with the V^+^ cell frequency ([Figure 2](#fig2){ref-type="fig"}A; no *Gata2* RNA analysis performed at day 11). To exclude the possibility that the later *Gata2* expression peaks are due to the remaining undifferentiated ESCs, we analyzed the expression of the Nanog pluripotency factor. *Nanog* RNA was significantly decreased after day 3 of differentiation and no protein was detected at d12 ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G). Also, *Brachyury* expression, indicative of primitive streak/mesoderm, showed the expected dynamics with increased expression at days 3--6, and was downregulated thereafter ([Figure S1](#mmc1){ref-type="supplementary-material"}H), thus supporting the likelihood of independent induction waves of *Gata2*^+^ hematopoietic cells in ESC cultures.Figure 2G2V Temporal Expression Defines Primitive and Definitive Hematopoietic Stages of ESC Differentiation(A) Percentage of Venus^+^ (V^+^) cells in day 4--14 *G2V* ESC cultures (n = 3).(B) Relative *Gata2* (left) and *Gata1* (right) *mRNA* as measured in qRT-PCR analysis of differentiated (total unsorted) cells from *G2V* ESC at days 4, 6, 8, 10, 12, and 14. Normalization to *β-actin* (n = 3).(C) Relative *Gata2*, *Tal1*, *Lyl1*, *Lmo2*, *Runx1*, *Fli1*, and *Erg mRNA* as measured in qRT-PCR analysis of V^+^ and V^−^ cells at days 6 (upper) and 12 (lower) of *G2V* ESC culture. Normalization to *β-actin* (n = 3).(D) qRT-PCR analysis of relative *Hbb-y* (*embryonic globin*), *βH1* (*embryonic globin*), and *βmajor* (adult globin) *mRNA* of cells from *G2V* differentiated ESCs at days 4, 6, 8, 10, 12, and 14. Normalization to *β-actin* (n = 3).(E) Confocal images (representative) of whole-mount stained day-6 (upper) and day-12 (lower) EBs. Venus, green; CD31, red. Arrows indicate flat endothelial-like V^+^ cells in day-6 EBs and round hematopoietic-like V^+^ cells/clusters in day-12 EBs. Scale bars, 40 μm. (E′) Magnification of whole-mount stained day-12 EB showing round V^+^ cells within the EB cavity close to CD31^+^ endothelial cells. Scale bar, 40 μm.(F) Bar graphs showing CFU-C per 10^4^ V^+^ and V^−^ cells from day-6 and day-12 *G2V* ESCs (n = 3). CFU-GEMM, granulocyte-erythrocyte, monocyte-macrophage; CFU-GM, granulocyte-macrophage; CFU-M, macrophage; CFU-G, granulocyte; BFU-E, definitive erythroid; CFU-EryP, primitive erythroid.Data are shown as means ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

*Gata2* functions in combination with other key (heptad) hematopoietic transcription factors to direct HPC/HSC development ([@bib50]). The expression of *Gata2*, *Tal1*, *Lyl1*, *Lmo2*, *Fli1*, *Runx1*, and *Erg* was tested (by qRT-PCR) in V^+^ and V^−^ sorted cells ([Figure 2](#fig2){ref-type="fig"}C). *Gata2*, *Tal1*, *Lyl1*, *Lmo2*, *Runx1*, and *Fli1* were significantly higher in the day-6 V^+^ compared with V^−^ cells. At day 12, *Gata2*, *Tal1*, *Lyl1*, and *Lmo2* were significantly higher in V^+^ compared with V^−^ cells. Similar expression levels of *Erg* were found in V^+^ and V^−^ cells at day 6/day 12, and *Runx1* and *Fli1* expression levels in these fractions were similar at day 12. As a control, the expression of a non-heptad ubiquitous transcription factor, *Cbfβ* (Runx1 binding partner), was assessed ([Figure S1](#mmc1){ref-type="supplementary-material"}I) and found to be similarly expressed in day-6 V^+^ and V^−^ cells. Thus, the expression of the relevant heptad hematopoietic transcription factors in ESC-derived Gata2^+^ cells indicates a developmental hematopoietic gene expression profile consistent with that found in mouse embryos ([@bib11]).

Sequential Waves of *Gata2*^+^ Cells Correlate with Functional Primitive and Definitive Hematopoietic Potential {#sec2.3}
---------------------------------------------------------------------------------------------------------------

Hematopoiesis in the mouse embryo occurs in stage-specific waves, with the generation of cells with progressively greater multipotent hematopoietic properties. To elucidate whether V^+^ cells in the sequential waves express genes indicative of primitive (*Hbb-y* and *βH1*; early erythroid) and/or definitive (*βmajor*; adult erythroid) programs ([@bib37], [@bib43]), we performed qRT-PCR ([Figure 2](#fig2){ref-type="fig"}D). *Gata1* (pan-erythroid factor) showed expression at days 6 to 14 ([Figure 2](#fig2){ref-type="fig"}B, right). *Hbb-y* was expressed from days 6 to 12 and decreased at day 14 ([Figure 2](#fig2){ref-type="fig"}D, upper), and *βH1* expression was detected from day 8 onward ([Figure 2](#fig2){ref-type="fig"}D, middle). Expression of both embryonic globins preceded the onset of *βmajor* (adult globin) expression that was detectable from day 10 onward ([Figure 2](#fig2){ref-type="fig"}D, lower), suggestive of definitive erythropoiesis.

In the mouse embryo, CD31^+^ HPCs/HSCs emerge from CD31^+^ HECs ([@bib2], [@bib52]). CD31^+^, V^+^, and CD31^+^V^+^ cells were detected in day-6 and day-12 embryoid bodies (EBs) ([Figures 2](#fig2){ref-type="fig"}E and 2E′). The morphology and localization of V^+^ cells in CD31 immunostained whole EBs was analyzed by confocal microscopy. At day 6, CD31^+^ cells were dispersed throughout the EBs with no distinct structural organization, and flat endothelial-like V^+^CD31^+^ cells were found ([Figure 2](#fig2){ref-type="fig"}E). At day 12, round hematopoietic-like V^+^CD31^+^ cells were closely associated with the CD31^+^ cells lining the EB cavities ([Figures 2](#fig2){ref-type="fig"}E \[lower\] and 2E′). These imaging data indicate that V^+^ cells in the day-6 and day-12 EBs are morphologically distinct, and thus may possess different functions.

To test the relationship between *Gata2* expression, stage of differentiation, and hematopoietic function, we harvested cells from day-6, -12, and -14 EBs, sorted V^+^ and V^−^ cells, and analyzed CFU-C. HPCs were found exclusively in the V^+^ cell fractions ([Figure 2](#fig2){ref-type="fig"}F). Day-6 V^+^ cells gave rise to 50.1 ± 13 CFU-C/10^4^ cells (1 HPC:198 cells), whereas day-12 V^+^ cells generated 36.0 ± 25 (1:278) and day-14 V^+^ cells 94.7 ± 20 CFU-C/10^4^ cells (1:278). The majority (67%) of day-6 cells had CFU-EryP potential. Only a low frequency of macrophage, granulocyte, and definitive erythroid (CFU-M, CFU-G, BFU-E) colonies were observed. In contrast, day-12 and day-14 cells gave rise to a variety of erythroid-myeloid colony types, including mixed multipotent colonies (CFU-GEMM), suggesting that day-12, but not day-6 V^+^ cells possess EMP potential. Moreover, the day-14 progenitor frequency was increased 2.6-fold compared with day 12, and more mixed multipotent colonies were detected ([Figure 2](#fig2){ref-type="fig"}F). CFU-C derived from day-12 to -14 progenitors exhibited significantly increased proliferation capacity compared with the CFU-C from day-6 EBs. Together these data indicate that Gata2^+^ cells represent at least two different stages of induction in ESC cultures that correlate with primitive and erythroid-myeloid definitive functional cell potentials and molecular programs.

Gata2*-*Expressing C-KIT^+^ Cells Show Phenotypic Markers Characteristic of Definitive Hematopoiesis {#sec2.4}
----------------------------------------------------------------------------------------------------

*G2V* ESCs were examined for C-KIT expression (marker of cells undergoing transition to the hematopoietic lineage) during the ESC differentiation culture. A high frequency of C-KIT^+^ cells was found at day 6 (∼64%) and decreased to ∼16% by days 10--14 ([Figure 3](#fig3){ref-type="fig"}A). The co-expression of C-KIT with CD31 (endothelial and hematopoietic marker), CD41 (HPC and megakaryocyte marker), CD45 (pan-hematopoietic), and CD16/32 (EMP marker co-expressed with C-KIT) was measured together with Venus expression on differentiated cells by FACS ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}). CD31^+^C-KIT^+^ cells were detected predominantly in V^+^ fraction, whereas very few V^−^ cells showed this phenotype. The percentages of CD31^+^C-KIT^+^ cells in the V^+^ fraction increased steadily at days 6--10, with a low point at day 12, and then rose again, suggesting a late wave of hematopoietic emergence. Four percent of day-6 V^+^C-KIT^+^ cells were CD41^+^ and this increased to 41% ± 3.3% at day 8, followed by decreases at days 10--14. Interestingly, C-KIT was mainly detected on V^+^CD41^lo^ and not V^+^CD41^hi^ cells, in line with published data showing that AGM HP/SCs express CD41 at low/intermediate levels ([@bib41]). Very few V^−^ cells were CD41^+^ throughout all time points analyzed, thus suggesting that co-expression of Gata2, CD41^lo^, and C-KIT define an HP/SC population during ESC differentiation. CD45 expression was barely detectable in V^+^C-KIT^+^ cells at day 6 (1.3%). There was a profound increase and peak at day 10 with 46% ± 2.2% of V^+^ cells CD45^+^C-KIT^+^ (as compared with the peak of CD41^+^C-KIT^+^ cells at day 8), and this was followed by decreased CD45^+^C-KIT^+^ cell percentages at days 12 and 14. No to very few V^−^ cells were CD45^+^C-KIT^+^ (0.4%--2.2%) throughout the differentiation. Thus, CD45 is confirmed as a later marker of hematopoietic cells. EMP markers CD16/32 were highly expressed at day 10. Eighty-five percent of day-10 V^+^C-KIT^+^ cells were CD16/32^+^, suggesting that the erythroid-myeloid CFU-C potential detected in the culture at days 12--14 emerges from CD16/32^+^V^+^ EMPs. In contrast to the other markers, CD16/32 was expressed also in V^−^ cells (15% ± 2.3% and 21% ± 5.0% at day 6). This is expected and is in line with the *in vivo* results showing *Gata2*-independent EMPs ([@bib20]). When the viability of day-10 to -14 V^+^ cells was tested ([Figure S1](#mmc1){ref-type="supplementary-material"}J) no profound change in cell viability was found, indicating that the decreased frequency in phenotypic HPCs is not related to cell death. Together, these data demonstrate that Gata2 expression defines most phenotypic HPCs generated throughout ESC differentiation (both early and later) and that these markers reveal wave-like cell kinetics.Figure 3Temporal Phenotypic Analysis of Reporter ESC-Derived Cells during Hematopoietic Differentiation(A--C) Percentage of C-KIT^+^ cells in total viable cells from differentiated (A) *G2V* (n = 6), (B) *LG* (n = 3), and (C) *LGGV* (day 6, n = 3; day 8 and day 12, n = 4; day 10, n = 7; day 14, n = 5) ESCs at days 6, 8, 10, 12, and 14.(D and E) Graphs showing the percentage of C-KIT^+^CD31^+^, C-KIT^+^CD41^+^, C-KIT^+^CD45^+^, and C-KIT^+^CD16/32^+^ cells in the reporter^+^ and reporter^−^ cells at days 6, 8, 10, 12, and 14. (D) *G2V* (V^+^, green; V^−^, black; n = 3); (E) *LG* ESCs (G^+^, red; G^−^, black; n = 4).(F) Graphs showing the percentage of C-KIT^+^CD31^+^, C-KIT^+^CD41^+^, C-KIT^+^CD45^+^ and C-KIT^+^CD16/32^+^ cells in V^+^G^+^ (blue), V^−^G^+^ (red), and V^+^G^−^ (green) cell fractions of *LGGV* ESCs at days 10, 12, and 14 (n \> 3).Data are shown as means ± SEM. Significant differences between reporter^+^ and reporter^−^ frequencies are indicated. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figures S3, S4, S6, and S7](#mmc1){ref-type="supplementary-material"}.

The *LG* Reporter Distinguishes a Late Hematopoietic Wave with Multilineage Potential {#sec2.5}
-------------------------------------------------------------------------------------

Unlike *G2V* reporter embryos in which Gata2 expression marks almost all hematopoietic cells from the earliest time of generation, the SCA1 (*LG*) reporter *in vivo* is expressed in fewer hematopoietic cells and in cells generated at later developmental stages ([@bib2], [@bib5]). Analysis of day-10 and day-14 *G2V* ESC cultures showed respectively that 3.7% and 2.2% of cells expressed SCA1 ([Figure 4](#fig4){ref-type="fig"}A). Of the day-10 SCA1^+^ cells, less than 1% were C-KIT^+^CD45^+^. Although a slightly higher percentage of SCA1^+^ cells was found in day-10 cultures, the day-14 cultures contained a 6-fold higher percentage of C-KIT^+^CD45^+^ cells in the SCA1^+^ fraction, indicating that the *LG* reporter may be a relevant tool to aid enrichment for hematopoietic progenitors late in ESC differentiation cultures.Figure 4LG Expression Distinguishes Functional Hematopoietic Cells in the Definitive ESC Differentiation Stage(A) FACS analysis of day-10 and day-14 *G2V* ESC for SCA1^+^ cells. Percentages of SCA1^+^ and SCA1^+^C-KIT^+^CD45^+^ cells are indicated (n = 3).(B) Percentage of G^+^ cells in cultures of differentiated *LG* ESCs at days 4--14 (n = 3).(C) Blast colony (BL-CFC) potential in G^+^ and G^−^ cells sorted from day-3 *LG* ESCs (n = 3).(D) FACS dot plot showing percentage of cells expressing FLK1 and/or GFP in day-3 *LG* ESC cultures (n = 3).(E) CFU-C potential of G^+^ and G^−^ cells from *LG* ESC cultures harvested at days 7, 10, 12, and 14 (CFU-C/10^4^; n = 4). Colony types correspond to color code. CFU-GEMM, granulocyte, erythrocyte, monocyte, macrophage; CFU-GM, granulocyte-macrophage; CFU-M, macrophage; CFU-G, granulocyte; BFU-E, definitive erythroid; CFU-EryP, primitive erythroid.(F) Time course of CFU-C frequency in cultures of *LG* ESC-derived G^+^ (red) and G^−^ (black) cells at days 7, 10, 12, and 14. Significant differences between CFU-C/10^4^ G^+^ and G^−^ cells are indicated (n = 4).(G) Lymphoid culture protocol used for differentiation and enrichment of G^+^ cells from *LG* ESCs.(H) B-lymphoid marker CD19 and B220 FACS of day-14 + day-22 CD45^+^ cells and CD19^+^B220^+^ (gated CD45^+^) cells from *LG* lymphoid differentiation cultures.Data are shown as means ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See [Figure S5](#mmc1){ref-type="supplementary-material"} for percentage (n = 5) and controls.

An *LG* ESC line was established from the *LG* mouse model to examine reporter expression kinetics during ESC differentiation. FACS analysis ([Figure 4](#fig4){ref-type="fig"}B) showed the presence of GFP^+^ (G^+^) cells already at days 3 (7%) and 4 (10%), followed by a rapid 5-fold decrease. G^+^ cell percentages increased at day 7 and peaked at days 9--10 of differentiation (3-fold increase; 6% at day 10).

The percentage of C-KIT^+^ cells in cultures at days 6--14 averaged ∼17% with little change ([Figure 3](#fig3){ref-type="fig"}B), indicating less efficient hematopoietic differentiation of the *LG* line compared with *G2V* line ([Figure 3](#fig3){ref-type="fig"}A). Next, C-KIT and co-expression of CD31, CD41, CD45, and CD16/32 within the G^+^ and G^−^ fractions of day-6 to -14 *LG* ESC cultures was determined ([Figures 3](#fig3){ref-type="fig"}E and [S4](#mmc1){ref-type="supplementary-material"}). At day 6 the percentages of CD31^+^C-KIT^+^ cells in G^+^ and G^−^ fractions, respectively (6.9% ± 0.4% and 6.9% ± 1.3%), were similar. From day 10 onward, the percentage of CD31^+^C-KIT^+^ cells increased in the G^+^ (rising to 26.0% ± 6.2%) compared with the G^−^ fraction. CD41^+^C-KIT^+^ cells were detected beginning at day 8 in G^+^ cells (0.9% ± 0.2%) and gradually increased to 14% ± 3.0% at day 14. Percentages of CD45^+^C-KIT^+^ showed a trend similar to that of CD41^+^C-KIT^+^ cells and were detected in the G^+^ fraction from day 8 (0.2% ± 0.1%) onward. The frequency increased significantly after day 12 and rose to 18% ± 5.1% at day 14. The G^−^ fraction contained no to very few CD45^+^C-KIT^+^ cells. C-KIT^+^CD16/32^+^ cells were detected from day 8 onward in both G^+^ and G^−^ fractions, with the frequency of C-KIT^+^CD16/32^+^ cells increasing considerably in the G^+^ fraction at days 10--12. These data indicate that *LG* reports phenotypic hematopoietic cells predominantly in the later stages of ESC differentiation.

The relationship of GFP expression with hematopoietic activity in the *LG* ESC culture was tested by blast colony-forming assay. At early differentiation stages (day 3), significantly more blast colonies (BL-CFC) per 10^4^ cells were found in the G^−^ fraction (215 ± 11) than in the G^+^ fraction (17 ± 12) ([Figure 4](#fig4){ref-type="fig"}C). Accordingly, very few FLK1^+^G^+^ cells were found (1% ± 0.1%) ([Figure 4](#fig4){ref-type="fig"}D). CFU-C assays from day-7 EBs revealed a small number of HPCs in both G^+^ and G^−^ fractions ([Figure 4](#fig4){ref-type="fig"}E). However, at days 12 and 14 significantly more CFU-Cs, including all the CFU-GEMMs, were found in the G^+^ fraction. CFU-C frequencies increased from day 7 to day 14 ([Figures 4](#fig4){ref-type="fig"}E and 4F) but were similar in the G^+^ and G^−^ fractions at days 7 and 10. A significantly higher frequency of CFU-C was in the G^+^ fraction than the G^−^ fraction at day 12, and at day 14 virtually all CFU-Cs were in the G^+^ fraction. This 2.3-fold increase in CFU-C frequency from day 12 to ay 14 indicates that the LG reporter enriches for late appearing HPCs.

To examine whether late appearing cells have B-lymphoid potential, we co-cultured day-14 *LG* EB-derived G^+^ cells for 22 days on OP-9 cells with lymphoid-promoting factors ([Figure 4](#fig4){ref-type="fig"}G). FACS analysis of B cell markers CD19 and B220 revealed that 4.3% ± 0.6% of the cells were CD19^+^CD45^+^ and 4.9% ± 0.8% were B220^+^CD45^+^. Seven percent of CD45^+^ were positive for both CD19 and B220 ([Figures 4](#fig4){ref-type="fig"}H and [S5](#mmc1){ref-type="supplementary-material"}). Thus, some *LG* reporter-expressing cells possess B-lymphoid potential.

Double Reporter Expression Defines Most HPCs in Late-Stage ESC Differentiation {#sec2.6}
------------------------------------------------------------------------------

To assess whether *G2V* and *LG* reporter expression is overlapping, we established a *Ly6a*(SCA1)*GFP*:*Gata2Venus* (*LGGV*) double ESC reporter line and examined the kinetics and frequency of reporter-expressing hematopoietic cells during differentiation ([Figures S6](#mmc1){ref-type="supplementary-material"}, [5](#fig5){ref-type="fig"}B, and 5C).Figure 5Late-Stage *LGGV* ESC Differentiation Cultures Contain a High Frequency of HPCs in the Double Reporter-Positive Population(A) CFU-C/10^4^ cells in day-12 (left; n = 6) and day-14 (right; n = 6) V^+^G^+^, V^+^G^−^, V^−^G^+^, and V^−^G^−^ fractions of differentiated *LGGV* ESCs. Color code indicates colony type.(B) FACS plots of viable reporter^+^ cells in day-12 (n = 8) and day-14 (n = 10) *LGGV* ESC differentiation cultures. Gated V^+^ (green), G^+^ (red), and V^+^G^+^ (blue) cells.(C) Percentage of V^+^ (green), G^+^ (red), and V^+^G^+^ (blue) cells in the total viable cells on days 6, 12, and 14 of *LGGV* ESC differentiation.Data are shown as means ± SEM. ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

The efficiency of *LGGV* ESC hematopoietic differentiation was determined by C-KIT FACS analysis at days 6, 8, 10, 12, and 14 ([Figure 3](#fig3){ref-type="fig"}C). The percentage of C-KIT^+^ cells in the total viable cell population of day-6 and -8 *LGGV* cultures was 37% and 34% respectively. At days 10--14, the cultures contained an average of 18% C-KIT^+^, thus indicating that the temporal hematopoietic differentiation efficiency of the *LGGV* line is similar to that of the *G2V* line ([Figure 3](#fig3){ref-type="fig"}A). Next, analysis for co-expression of C-KIT and CD31, CD41, CD45, or CD16/32 within the V^+^G^+^, V^+^G^−^, and V^−^G^+^ fractions of day-10, -12, and -14 ESC differentiation cultures was performed ([Figures 3](#fig3){ref-type="fig"}F and [S7](#mmc1){ref-type="supplementary-material"}). In general, the highest percentage of C-KIT^+^CD31^+^, C-KIT^+^CD41^+^, C-KIT^+^CD45^+^, and C-KIT^+^CD16/32^+^ cells was in the V^+^G^+^ fraction at all three time points. Moreover, at day 14 for all the markers except for C-KIT^+^CD41^+^, significant increases in the percentages of marker-positive cells were found in the V^+^G^+^ fraction as compared with the V^+^G^−^ and/or V^−^G^+^ fractions, indicating a late shift in phenotypic hematopoietic progenitors.

To determine in which reporter-expressing populations HPC function was localized, we differentiated *LGGV* ESCs, and analyzed day-12 and day-14 single (V^+^G^−^ and V^−^G^+^) and double (V^+^G^+^) reporter-expressing cells along with reporter-negative (V^−^G^−^) cells ([Figure 5](#fig5){ref-type="fig"}A). At day 12, 119 CFU-C/10^4^ were detected, of which 57 were derived from V^+^G^−^ and 62 from V^+^G^+^ fractions. Negligible to no CFU-Cs were present in the V^−^G^+^ or V^−^G^−^ fractions. The CFU-C frequency at day 14 increased to 200/10^4^ cells, and all CFU-GEMM were in the V^+^G^+^ fraction ([Figure 5](#fig5){ref-type="fig"}A). Interestingly, when taking into account the frequency of reporter-expressing cells in the total cell population derived from *LGGV* EBs ([Figures 5](#fig5){ref-type="fig"}A and 5B), overall CFU-C frequency in the day-14 V^+^G^+^ versus V^+^G^−^ fraction increased 4-fold (from 5% to 20% of the total colonies) compared with day 12 ([Figure 6](#fig6){ref-type="fig"}A, lower). This is in line with the increase in CFU-C frequency in the G^+^ versus G^−^ fractions derived from day-12 and day-14 *LG* cultures ([Figure 6](#fig6){ref-type="fig"}A, middle). Colonies derived from *G2V* cultures were found only within the V^+^ fraction throughout differentiation ([Figure 6](#fig6){ref-type="fig"}A, upper).Figure 6Temporal Distribution of Hematopoietic Progenitors in Reporter ESC Differentiation Cultures(A) Percentage of CFU-C/10^4^ cells in day-6, -12, and -14 differentiated *G2V* ESC-derived V^+^ cells (green) (upper); in day-7, -12, and -14 differentiated *LG* ESC-derived G^+^ (red) and G^−^ cells (white) (middle); and in day-12 and -14 differentiated *LGGV* ESC-derived V^+^G^+^ (blue) and V^+^ cells (green) (lower). CFU-C frequencies are calculated based on the percentage of respective reporter-expressing cells in the total population.(B) Time-course model showing waves of primitive, erythroid-myeloid-definitive, and B-lymphoid-definitive hematopoietic progenitor activities in multireporter ESC differentiation cultures.

Together, these data suggest that a subset of progenitors is generated and/or gradually acquires the LG marker later in the culture and possesses more complex hematopoietic potential, thereby distinguishing and allowing specific enrichment of a more potent definitive wave of ESC hematopoietic emergence.

Discussion {#sec3}
==========

In this study, we show that ESC differentiation progresses through stages of functional hematopoietic cell production that can be discriminated by the *G2V* and/or *LG* reporters ([Figure 6](#fig6){ref-type="fig"}B). The fact that these reporters are validated *in vivo* indicators of normal temporal and spatial generation of functional hematopoietic cells in the mouse embryo ([@bib5], [@bib20], [@bib28], [@bib46]) ensures high fidelity in their use to examine the stages of hematopoietic emergence *in vitro*. The reporter-expressing ESC-derived cells exhibit functional hematopoietic properties that correspond to cells generated in the *in vivo* waves of hematopoietic emergence.

Hematopoiesis in the mouse embryo starts in the YS with a transient wave of primitive hematopoiesis, and is characterized by FLK1^+^ cells that give rise to the earliest blood cells and endothelium ([@bib4], [@bib23], [@bib38], [@bib45]). Our analysis of early *G2V* EB differentiation (days 4--6) reveals a transient FLK1^+^V^+^ population that differentiates into endothelial and/or primitive erythroid cells. In contrast, early *LG* EB differentiation shows that most FLK1 expression is in the G^−^ cell fraction and blast colony-forming activity is in the FLK^+^ and G^−^ cell fraction. Thus, *G2V* but not *LG* reports the earliest onset of hematopoietic potential in ESCs.

V^+^ cells, albeit very few, are already present at day 4 of *G2V* ESC differentiation. It was difficult to detect *Gata2*, *Gata1*, and globin gene expression at day 4 ([Figure 2](#fig2){ref-type="fig"}B) by qRT-PCR of total *G2V* EB RNA. Others have shown, by single cell transcriptomics performed on pseudotemporally ordered E7.5--7.75 FLK1^+^ mesodermal cells, an upregulation of *Gata1*, *βH1*, and *Itga2b* (CD41) following *Brachyury* expression during primitive streak specification ([@bib44]). In total EB RNA, we found *Brachyury* expression at days 3 and 6 ([Figure S1](#mmc1){ref-type="supplementary-material"}H), indicating that at least some differentiating EBs closely follow the formation of early mesoderm in gastrulating embryos. *Gata1* and *Gata2* expression was initiated at days 4--6. Embryonic globin *Hbby* and *βH1* expression began at days 4--6 and 6--8, respectively, and adult globin (*βmajor*) expression began at days 8--10 ([Figure 2](#fig2){ref-type="fig"}D) although its levels were relatively low. These data are somewhat in agreement with those found in the mouse embryo ([@bib43]). *βH1* expression begins in the YS at E7.5 ([@bib26]), with only very low levels of *Hbby* and *βmajor* expression. *Hbby* expression is high in the E10.5 and E15.5 peripheral blood, and *βmajor* expression is high in the enucleated E15.5 erythrocytes. Thus, while the general onset of expression of the embryonic globins prior to *βmajor* expression is similar to *in vivo* expression, the other differences seen in the ESC differentiation cultures are likely due to heterogeneous cell growth and frequency.

Interestingly, a decreased frequency of CFU-EryP in the V^+^ fraction corresponded with the onset of the second *Gata2* expression wave at days 10--11 that is accompanied by expression of adult globin and the appearance of EMPs ([Figure 2](#fig2){ref-type="fig"}F). Thus, the *Gata2* expression peaks discriminate functional primitive and definitive stages in the ESC differentiation. It is likely that these waves derive from independent cohorts of cells as supported by transcriptomic ([@bib44]) and hESC differentiation data ([@bib7], [@bib47]), but contrasts with data suggesting that all waves of hematopoietic activity and *in vivo* repopulating cells arise as early as day 3 ([@bib39]). Additionally, the temporal dynamics of Gata2-defined primitive/definitive stages are consistent with studies reporting hemogenic endothelium and hematopoietic cell generation in mouse ESC and hESC differentiation cultures ([@bib35], [@bib36], [@bib54]). Although all CFU-Cs were obtained in the V^+^ cell fraction, FACS analysis revealed some phenotypic HPCs in the V^−^ fraction. Hence, we cannot rule out that some early HPCs may be at low frequency in the V^−^ fraction as was found *in vivo* ([@bib20]).

Morphological observation of V^+^ cells in the differentiating EBs corroborates both developmental and functional stage changes. Day-12 (but not day-6) EBs show CD31^+^ cells lining vascular tubules and the close association of clusters of V^+^CD31^+^ cells, mainly near the EB cavities ([Figures 2](#fig2){ref-type="fig"}E and 2E′). This is supported by FACS data showing an increased frequency of C-KIT^+^CD31^+^V^+^ cells after day 6 ([Figure 3](#fig3){ref-type="fig"}D). Most probably it represents the EHT detected in E8.25--11 circulation-deficient YS where EMPs emerge in C-KIT^+^ cell clusters ([@bib12]). Although a recent study with day-23 to -33 differentiated hESCs showed similar aortic and cluster-like structures ([@bib36]), it as yet uncertain, due to the heterogeneity of our cultures, whether they contain the CD31^+^V^+^ aortic endothelial and CD31^+^C-KIT^+^V^+^ intra-aortic hematopoietic cluster cells equivalent to E10.5 *G2V* AGM tissue ([@bib20]).

Surface marker analysis of *G2V* ESC-derived cells revealed that the highest frequency of phenotypic V^+^C-KIT^+^CD41^+^ hematopoietic cells is at day 8, whereas V^+^C-KIT^+^CD45^+^, V^+^C-KIT^+^CD16/32^+^, and V^+^C-KIT^+^CD31^+^ cells peak at day 10 ([Figure 3](#fig3){ref-type="fig"}D). Thereafter their frequency is greatly reduced. These dynamics may reflect early stages of myeloid differentiation. However, our FACS data (not shown) indicate that the differentiated blood cells are within the V^−^ cell compartment, supporting the view that the V^+^ cell waves reflect different progenitor emergence stages. This is in line with several hESC expression profiling and surface marker studies that suggest waves of hematopoietic generation followed by blood cell maturation ([@bib19], [@bib35], [@bib54]). Thus, the second wave of ESC V^+^ hematopoietic cell production functionally, morphologically, and phenotypically resembles *in vivo* definitive hematogenesis in the YS.

HPC potential in our ESC differentiation cultures continues at day 12 and thereafter, and *LG* reporter expression identifies all definitive HPCs at these late time points. LG did not enrich for primitive stage blast-cell progenitors, nor for HPCs during the first stage of EB differentiation (e.g., days 6--10). This contrasts with *G2V* ESCs where all HPCs are V^+^ throughout the differentiation. From day 12 onward, HPC activity is significantly enriched in G^+^ fraction, and at day 14 some G^+^ cells possess B-lymphoid potential. Distribution of HPC activity in the *LG* EBs is consistent with the distribution in the *LG* mouse embryos. In the *LG* YS, most HPCs are G^−^ whereas AGM lymphoid progenitors at E10 and multipotent HPCs/HSC are at much higher frequency in the E10.5/11.5 G^+^ than in the G^−^ fraction ([@bib5], [@bib28], [@bib46]). In the E10.5 aorta, *LG* expression reports hemogenic endothelial cells transitioning to HSCs ([@bib2]). Thus, *LG* expression *in vivo* specifically reports aortic HSCs and cells with lymphoid potential, but not the YS-stage progenitors. Although there is consistency between our *in vitro LG* ESC results and *in vivo LG* mouse data, it is as yet uncertain whether the ESC-derived definitive G^+^ progenitors that have B-lymphoid potential represent an aorta-like or YS-definitive program, as lymphoid potential has also been demonstrated in the YS independently from arterial identity ([@bib12], [@bib53]).

Importantly, our *LGGV* double reporter ESC line shows that these late G^+^ HPC co-express Gata2, thus facilitating high enrichment of multipotent progenitors that are generated in late ESC differentiation cultures. In some preliminary short-term transplantation experiments (4 × 10^4^ V^+^ cells from day-12 or -14 differentiated *G2V* ESCs) we were unable to detect donor-derived spleen colonies. Such short-term and long-term transplantation experiments with the *LGGV* ESC line are planned after further optimization of the differentiation cultures and flow-cytometric enrichment.

In conclusion, we demonstrate that different stages of HPC generation can be prospectively isolated by the *G2V* and/or *LG* reporter expression in ESC differentiation cultures. Such findings facilitate a better understanding of the hematopoietic development in ESC differentiation cultures, and should ultimately enable the recapitulation of robust physiologic HSC emergence for the *de novo* generation of transplantable HSCs.

Experimental Procedures {#sec4}
=======================

ESC *In Vitro* Differentiation {#sec4.1}
------------------------------

ESCs (WT, *G2V*, *LG*, *LGGV*) were established from 129/Ola, *Gata2Venus* ([@bib20]), *Ly6a*(SCA1)*GFP* ([@bib5]), and (*Gata2Venus × Ly6a*(SCA1)*GFP*)F1 day-3.5 blastocysts cultured on irradiated mouse embryonic fibroblasts (MEFs) in SR-ES medium (KO DMEM + 20% KO Serum Replacement + 1% penicillin/streptomycin \[P/S\] + 2 mM L-glutamine + 1× non-essential amino acids \[NEAA\] \[all Gibco\] + 100 mM β-mercaptoethanol \[Sigma\] + recombinant mouse leukemia inhibitory factor \[LIF; 1,000 U/mL; Chemicon International\]). To allow for inner cell mass expansion the medium was changed every 2 days and cells were trypsinized, transferred to 12-well MEF-coated plates, and maintained in DMEM (Lonza) + 15% fetal bovine serum (FBS; HyClone) + 2 mM GlutaMAX + 1 mM Na-pyruvate + 1% P/S + 50 μM β-mercaptoethanol (all Gibco) + 0.1 mM NEAA (Lonza) + 1,000 U/mL LIF (Sigma) at 37°C and 5% CO~2~. MEFs were depleted by 30-min incubation in EB medium (Iscove's modified Dulbecco's medium \[IMDM\] + 15% fetal calf serum \[HyClone\] + 1% P/S \[Gibco\]). EB formation was induced (40 rpm; 25 × 10^3^ cells/mL) in EB medium + 2 mM GlutaMAX (Gibco) + 50 μg/mL ascorbic acid (Sigma) + 4 × 10^−4^ M monothioglycerol (Sigma) + 300 μg/mL transferrin (Roche) and supplemented with 5% proteome-free hybridoma medium (Gibco) on day 3. From day 6 onward, 100 ng/mL stem cell factor (SCF) + 1 ng/mL interleukin-3 (IL-3) + 5 ng/mL IL-11 were added. For blast-cell cultures, 5 ng/mL BMP4 was added on days 0--3. All factors were from PeproTech.

FACS {#sec4.2}
----

PBS-washed EBs were incubated (37°C, 3--5 min) in TrypLE Express (Gibco). PBS + 10% FBS + 1% P/S was added and single cells suspended (P1000 pipette). 10^6^ cells per 100 μL were immunostained (30 min on ice) ([Table S1](#mmc1){ref-type="supplementary-material"}). Dead cells were Hoechst 33342 (Invitrogen) excluded. LSRFortessa, FACScan, FACSAria III/Fusion (Becton Dickinson) and FlowJo software (TreeStar) were used. Strategy for detection of GFP and/or Venus is described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} and [Figure S6](#mmc1){ref-type="supplementary-material"}.

CFU-C Assays {#sec4.3}
------------

For BL-CFC, day-3 EB cells were plated in methylcellulose (STEMCELL Technologies) + 10% FCS + vascular endothelial growth factor (5 ng/mL) + IL-6 (10 ng/mL) (PeproTech). After 4 days, BL-CFC (grape-like multicellular structures \[[@bib24]\]) were microscopically counted. D6-14 EB cells were plated in methylcellulose (1 mL/dish, M3434; STEMCELL Technologies) + IMDM + FBS + BSA + recombinant human insulin + human transferrin (iron-saturated) + 2-mercaptoethanol + recombinant SCF + recombinant IL-3 + recombinant IL-6 + recombinant human erythropoietin. After 12--14 days, colonies were scored (Zeiss Axiovert25).

Matrigel Assay {#sec4.4}
--------------

Day-4 EB cells (2 × 10^4^) from each FLK1/Venus fraction ([Figure 1](#fig1){ref-type="fig"}B) were pre-cultured in gelatin-coated 96-well plates (DMEM + 20% FBS + 1% P/S; 20 hr). Cells were trypsinized, transferred to Matrigel-coated (60 μL Matrigel/well, 30 min, 37°C; Qiagen) 96-well plates and cultured in EGM-2 (Lonza) for 4 hr. Tubules were quantified by the Angiogenesis Analyzer (Gilles Carpentier ImageJ News, 2012) plugin for Fiji.

Transcription Analysis {#sec4.5}
----------------------

Up to 10^6^ cells were lysed and total RNA isolated (TRI-Reagent, MRC). RNA (1 μg) was DNase (Invitrogen) treated. RNA from sorted cells was isolated using an RNeasy kit (Qiagen). cDNA was synthesized with oligo(dT) (Invitrogen) and SuperScriptIII (Life Technologies). qRT-PCR was performed with FastSybrGreen master mix (Life Technologies) and primers ([Table S2](#mmc1){ref-type="supplementary-material"}).

B-Lymphoid Culture {#sec4.6}
------------------

At day 6 of ESC differentiation, 100 ng/mL SCF + 1 ng/mL IL-3 + 5 ng/mL IL-11 + 5 ng/mL FLT3L were added and medium replaced every other day. On day 14, EBs were dissociated and 5--10 × 10^4^ FACS-sorted cells plated on OP9 (plated at −1 day in a 6-well plate) in 2 mL of α-minimal essential medium + 20% FBS + 1% P/S + 5 ng/mL IL-7 + 5 ng/mL FLT3L. Every 4--6 days, cells were replated on OP9 and harvested on day 22. The FACS strategy is displayed in [Figure S5](#mmc1){ref-type="supplementary-material"}.

Whole-Mount Staining {#sec4.7}
--------------------

EB staining was performed as in [@bib52]. EBs were washed in PBS, fixed in PBS + 2% paraformaldehyde (Sigma) for 10 min, washed in PBS (×3), and dehydrated in 50% methanol + PBS and 100% methanol (10 min, ×2). EBs were rehydrated in 1:1 methanol/PBS (10 min) and 100% methanol (10 min), washed in PBS (10 min on ice), and blocked in PBS + 1% semi-skimmed milk + 0.005% Tween 20 (Sigma) (PBS-MT) + 10% BSA (Sigma) + 0.1% goat serum (4--6 hr). Antibody ([Table S1](#mmc1){ref-type="supplementary-material"}) staining was performed (4°C) in PBS-MT and EBs washed in PBS-MT (\>2 hr ×3), in 100% methanol (30 s, ×4) in a fast well, cleared in 1:1 benzyl alcohol benzyl benzoate (BABB)/methanol (30 s) followed by 100% BABB, overlaid with a coverslip, and imaged (Leica SP5).

Statistics {#sec4.8}
----------

Unpaired Student\'s t test or one-way ANOVA with Bonferroni correction for multiple comparisons were used (GraphPad). Results were statistically significant at p \< 0.05 (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 in figures). All data are shown as mean ± SEM. n denotes the number of biological replicates.
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